+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market, Forecast 2022-2027, Industry Trends, Impact of COVID-19, Company Analysis

  • PDF Icon

    Report

  • 175 Pages
  • March 2022
  • Region: Global
  • Renub Research
  • ID: 5562702
Global Non-Small Cell Lung Cancer (NSCLC) Market will reach US$ 25.71 Billion in 2027. Globally, lung cancer is one of the most frequent types of cancer, with two distinct subtypes. The non-small cell lung cancer subtype accounts for most lung cancer cases (NSCLC). Furthermore, lung cancer, as one of the most common malignancies in the world, is responsible for a considerable number of deaths globally. As a result of the expanding frequency and incidence of non-small cell lung cancer across all demographics and age categories, demand for non-small cell lung cancer therapies has increased.

COVID-19 Impact on Non-Small Cell Lung Cancer Treatment (NSCLC) Industry:


Non-Small Cell Lung Cancer Treatment (NSCLC) Market represented a central challenge in clinical diagnosis and therapy decision-making in the context of the favorably contagious COVID-19 pandemic. Even for patients who were non-COVID-19, the disturbance of regular hospital services, such as imaging and treatment appointments, had a significant impact on the physical and mental well-being of these patients. The stress placed on the availability of medical resources and hospitals has reduced the clinical admissions to most other departments, including oncology departments. Consequently, the benefits some cancer patients could have received have been compromised due to treatment delay declining the market in 2020.

Worldwide Non-Small Cell Lung Cancer (NSCLC) Market Size has reached US$ 17.75 Billion in 2021


The rise of the non-small cell lung cancer therapy (NSCLC) market has been fuelled by the increased number of non-small cell lung cancer diagnoses and increased awareness in developed and emerging countries. Other reasons contributing to the expansion of the non-small cell lung cancer treatments market include an increase in the proportion of smokers and exposure to toxins such as asbestos. According to our estimates, the Non-Small Cell Lung Cancer (NSCLC) Market will grow at a 6.4% CAGR from 2021 to 2027.

Adenocarcinoma Is the Most Prevalent Segment Histologically:


Our report classified the histological segment into three categories: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Compared to the other two forms, adenocarcinoma is the most common and is found in the cells responsible for mucous secretion in the outer lung sections. Furthermore, Squamous Cell Carcinoma, located in the squamous cells near the bronchus in the middle of the lungs, is one of the fastest expanding segments in the market. Large cell carcinoma, also known as undifferentiated carcinoma, can develop in any section of the lungs, is the fastest-growing, and is the most difficult to cure.

Immunotherapy Market Share is Estimated to Be the Largest:


By treatment, immunotherapy is expected to have the most significant market share. According to our estimates, the targeted therapy category will grow during the projection period. The increasing number of product launches, particularly in the immunotherapy area, is credited with the market domination. Immunotherapy is currently being used more widely in emerging countries, owing to improved patient outcomes resulting from effective treatment.

Regional Analysis:


In our report, we have examined the regions like North America, Europe, Asia-Pacific, Rest of The World. Lung cancer is becoming more common, and innovative therapies and are becoming more widely used, making the North America, Europe & Asia Pacific the most powerful region worldwide. Due to a rise in lung cancer diagnoses, India and China in the Asia Pacific region are seeing growth in NSCLC therapies. Chemotherapy is the most common kind of treatment in these underdeveloped countries. However, advanced immunotherapies and targeted medicines are seeing rising adoption and investment in nations like United States, Germany, United Kingdom, and Japan.

Key Market Players:


Our report examines AbbVie Inc., Astellas Pharma, AstraZeneca, Avid Bioservices Inc., Bayer Healthcare, Biogen Inc., Blueprint Medicines Corp, Eli Lilly and Company, Merck & Co Inc., Novartis, and Pfizer Inc. as leading players in the Non-Small Cell Lung Cancer Treatment (NSCLC) Market. The majority of significant market players are also concentrating on continuous advancements in advanced therapies and improving the efficacy of existing medicines. These businesses are receiving product approvals as well.

The publisher's latest report Non-Small Cell Lung Cancer Treatment (NSCLC) Market, Global Forecast By Histology Type (Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma), Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, Targeted Therapy Drugs), Drug Class (Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, PD-1/ PD-L1 Inhibitor), End User (General Medical & Surgical Hospitals, Specialty Hospitals, Clinics, Others), Region (North America, Europe, Asia-Pacific, Rest of The World), Companies (AbbVie Inc., Astellas Pharma, AstraZeneca, Avid Bioservices Inc., Bayer Healthcare, Biogen Inc., Blueprint Medicines Corp, Eli Lilly and Company, Merck & co Inc., Novartis, Pfizer Inc.) provides a detailed analysis of Non-Small Cell Lung Cancer Treatment (NSCLC) Industry.

Histology Type - Market has been covered from 3 viewpoints:


1. Adenocarcinoma
2. Squamous Cell Carcinoma
3. Large Cell Carcinoma

Treatment Type - Market has been covered from 5 viewpoints:


1. Chemotherapy
2. Immunotherapy
3. Radiation Therapy
4. Surgery
5. Targeted Therapy Drugs

Drug Class - Market has been covered from 6 viewpoints:


1. Angiogenesis Inhibitor
2. Epidermal Growth Factor Receptor Blocker
3. Kinase Inhibitor
4. Microtubule Stabilizer
5. Folate Antimetabolites
6. PD-1/ PD-L1 Inhibitor

End User - Market has been covered from 4 viewpoints:


1. General Medical & Surgical Hospitals
2. Specialty Hospitals
3. Clinics
4. Others

Region - Market has been covered from 4 viewpoints:


1. North America
2. Europe
3. Asia-Pacific
4. Rest of The World

Company Insights:


  • Overview
  • Recent Development
  • Revenue

Key Players:


1. AbbVie Inc.
2. Astellas Pharma
3. AstraZeneca
4. Avid Bioservices Inc.
5. Bayer Healthcare
6. Biogen Inc.
7. Blueprint Medicines Corp
8. Eli Lilly and Company
9. Merck & co Inc.
10. Novartis
11. Pfizer Inc.
Frequently Asked Questions about the Global Non-Small Cell Lung Cancer Market

What is the estimated value of the Global Non-Small Cell Lung Cancer Market?

The Global Non-Small Cell Lung Cancer Market was estimated to be valued at $17.75 Billion in 2021.

What is the growth rate of the Global Non-Small Cell Lung Cancer Market?

The growth rate of the Global Non-Small Cell Lung Cancer Market is 6.4%, with an estimated value of $25.71 Billion by 2027.

What is the forecasted size of the Global Non-Small Cell Lung Cancer Market?

The Global Non-Small Cell Lung Cancer Market is estimated to be worth $25.71 Billion by 2027.

Who are the key companies in the Global Non-Small Cell Lung Cancer Market?

Key companies in the Global Non-Small Cell Lung Cancer Market include AbbVie Inc., Astellas Pharma, AstraZeneca, Avid Bioservices Inc., Bayer Healthcare, Biogen Inc., Blueprint Medicines Corp, Eli Lilly and Company and Novartis.

Table of Contents

1. Introduction2. Research & Methodology3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Non-Small Cell Lung Cancer Treatment (NSCLC) Market
6. Market Share Analysis - Non-Small Cell Lung Cancer Treatment (NSCLC)
6.1 By Histology Type
6.2 By Treatment Type
6.3 By Drug Class
6.4 By End User
6.5 By Region
7. Histology Type - Non-Small Cell Lung Cancer Treatment (NSCLC) Market
7.1 Adenocarcinoma
7.2 Squamous Cell Carcinoma
7.3 Large Cell Carcinoma
8. Treatment Type - Non-Small Cell Lung Cancer Treatment (NSCLC) Market
8.1 Chemotherapy
8.2 Immunotherapy
8.3 Radiation Therapy
8.4 Surgery
8.5 Targeted Therapy Drugs
9. Drug Class - Non-Small Cell Lung Cancer Treatment (NSCLC) Market
9.1 Angiogenesis Inhibitor
9.2 Epidermal Growth Factor Receptor Blocker
9.3 Kinase Inhibitor
9.4 Microtubule Stabilizer
9.5 Folate Antimetabolites
9.6 PD-1/ PD-L1 Inhibitor
10. End User - Non-Small Cell Lung Cancer Treatment (NSCLC) Market
10.1 General Medical & Surgical Hospitals
10.2 Specialty Hospitals
10.3 Clinics
10.4 Others
11. Region - Non-Small Cell Lung Cancer Treatment (NSCLC) Market
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Rest of The World
12. Porters Five Forces
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13. Key Players
13.1 AbbVie Inc.
13.1.1 Overview
13.1.2 Recent Development
13.1.3 Revenue
13.2 Astellas Pharma
13.2.1 Overview
13.2.2 Recent Development
13.2.3 Revenue
13.3 AstraZeneca
13.3.1 Overview
13.3.2 Recent Development
13.3.3 Revenue
13.4 Avid Bioservices Inc.
13.4.1 Overview
13.4.2 Recent Development
13.4.3 Revenue
13.5 Bayer Healthcare
13.5.1 Overview
13.5.2 Recent Development
13.5.3 Revenue
13.6 Biogen Inc.
13.6.1 Overview
13.6.2 Recent Development
13.6.3 Revenue
13.7 Blueprint Medicines Corp
13.7.1 Overview
13.7.2 Recent Development
13.7.3 Revenue
13.8 Eli Lilly and Company
13.8.1 Overview
13.8.2 Recent Development
13.8.3 Revenue
13.9 Merck & co Inc.
13.9.1 Overview
13.9.2 Recent Development
13.9.3 Revenue
13.10 Novartis
13.10.1 Overview
13.10.2 Recent Development
13.10.3 Revenue
13.11 Pfizer Inc.
13.11.1 Overview
13.11.2 Recent Development
13.11.3 Revenue
List Of Figures:
Figure 01: Global - Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Billion US$), 2016 - 2021
Figure 02: Global - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Billion US$), 2022 - 2027
Figure 03: Histology Type - Adenocarcinoma Market (Million US$), 2016 - 2021
Figure 04: Histology Type - Forecast for Adenocarcinoma Market (Million US$), 2022 - 2027
Figure 05: Histology Type - Squamous Cell Carcinoma Market (Million US$), 2016 - 2021
Figure 06: Histology Type - Forecast for Squamous Cell Carcinoma Market (Million US$), 2022 - 2027
Figure 07: Histology Type - Large Cell Carcinoma Market (Million US$), 2016 - 2021
Figure 08: Histology Type - Forecast for Large Cell Carcinoma Market (Million US$), 2022 - 2027
Figure 09: Treatment Type - Chemotherapy Market (Million US$), 2016 - 2021
Figure 10: Treatment Type - Forecast for Chemotherapy Market (Million US$), 2022 - 2027
Figure 11: Treatment Type - Immunotherapy Market (Million US$), 2016 - 2021
Figure 12: Treatment Type - Forecast for Immunotherapy Market (Million US$), 2022 - 2027
Figure 13: Treatment Type - Radiation Therapy Market (Million US$), 2016 - 2021
Figure 14: Treatment Type - Forecast for Radiation Therapy Market (Million US$), 2022 - 2027
Figure 15: Treatment Type - Surgery Market (Million US$), 2016 - 2021
Figure 16: Treatment Type - Forecast for Surgery Market (Million US$), 2022 - 2027
Figure 17: Treatment Type - Targeted Therapy Drugs Market (Million US$), 2016 - 2021
Figure 18: Treatment Type - Forecast for Targeted Therapy Drugs Market (Million US$), 2022 - 2027
Figure 19: Drug Class - Angiogenesis Inhibitor Market (Million US$), 2016 - 2021
Figure 20: Drug Class - Forecast for Angiogenesis Inhibitor Market (Million US$), 2022 - 2027
Figure 21: Drug Class - Epidermal Growth Factor Receptor Blocker Market (Million US$), 2016 - 2021
Figure 22: Drug Class - Forecast for Epidermal Growth Factor Receptor Blocker Market (Million US$), 2022 - 2027
Figure 23: Drug Class - Kinase Inhibitor Market (Million US$), 2016 - 2021
Figure 24: Drug Class - Forecast for Kinase Inhibitor Market (Million US$), 2022 - 2027
Figure 25: Drug Class - Microtubule Stabilizer Market (Million US$), 2016 - 2021
Figure 26: Drug Class - Forecast for Microtubule Stabilizer Market (Million US$), 2022 - 2027
Figure 27: Drug Class - Folate Antimetabolites Market (Million US$), 2016 - 2021
Figure 28: Drug Class - Forecast for Folate Antimetabolites Market (Million US$), 2022 - 2027
Figure 29: Drug Class - PD-1/ PD-L1 Inhibitor Market (Million US$), 2016 - 2021
Figure 30: Drug Class - Forecast for PD-1/ PD-L1 Inhibitor Market (Million US$), 2022 - 2027
Figure 31: End User - General Medical & Surgical Hospitals Market (Million US$), 2016 - 2021
Figure 32: End User - Forecast for General Medical & Surgical Hospitals Market (Million US$), 2022 - 2027
Figure 33: End User - Specialty Hospitals Market (Million US$), 2016 - 2021
Figure 34: End User - Forecast for Specialty Hospitals Market (Million US$), 2022 - 2027
Figure 35: End User - Clinics Market (Million US$), 2016 - 2021
Figure 36: End User - Forecast for Clinics Market (Million US$), 2022 - 2027
Figure 37: End User - Others Market (Million US$), 2016 - 2021
Figure 38: End User - Forecast for Others Market (Million US$), 2022 - 2027
Figure 39: North America - Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2016 - 2021
Figure 40: North America - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2022 - 2027
Figure 41: Europe - Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2016 - 2021
Figure 42: Europe - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2022 - 2027
Figure 43: Asia-Pacific - Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2016 - 2021
Figure 44: Asia-Pacific - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2022 - 2027
Figure 45: Rest of the World - Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2016 - 2021
Figure 46: Rest of the World - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2022 - 2027
Figure 47: AbbVie Inc. - Global Revenue (Million US$), 2016 - 2021
Figure 48: AbbVie Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 49: Astellas Pharma - Global Revenue (Million US$), 2016 - 2021
Figure 50: Astellas Pharma - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 51: AstraZeneca - Global Revenue (Million US$), 2016 - 2021
Figure 52: AstraZeneca - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 53: Avid Bioservices Inc. - Global Revenue (Million US$), 2016 - 2021
Figure 54: Avid Bioservices Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 55: Bayer Healthcare - Global Revenue (Million US$), 2016 - 2021
Figure 56: Bayer Healthcare - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 57: Biogen Inc. - Global Revenue (Million US$), 2016 - 2021
Figure 58: Biogen Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 59: Blueprint Medicines Corp - Global Revenue (Million US$), 2016 - 2021
Figure 60: Blueprint Medicines Corp - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 61: Eli Lilly and Company - Global Revenue (Million US$), 2016 - 2021
Figure 62: Eli Lilly and Company - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 63: Merck & co Inc. - Global Revenue (Million US$), 2016 - 2021
Figure 64: Merck & co Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 65: Novartis - Global Revenue (Million US$), 2016 - 2021
Figure 66: Novartis - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 67: Pfizer Inc. - Global Revenue (Million US$), 2016 - 2021
Figure 68: Pfizer Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
List Of Tables:
Table 01: Global - Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Histology Type (Percent), 2016 - 2021
Table 02: Global - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Histology Type (Percent), 2022 - 2027
Table 03: Global - Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Treatment Type (Percent), 2016 - 2021
Table 04: Global - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Treatment Type (Percent), 2022 - 2027
Table 05: Global - Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Drug Class (Percent), 2016 - 2021
Table 06: Global - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Drug Class (Percent), 2022 - 2027
Table 07: Global - Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by End-User (Percent), 2016 - 2021
Table 08: Global - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by End-User (Percent), 2022 - 2027
Table 09: Global - Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Region (Percent), 2016 - 2021
Table 10: Global - Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Region (Percent), 2022 - 2027

Companies Mentioned

  • AbbVie Inc.
  • Astellas Pharma
  • AstraZeneca
  • Avid Bioservices Inc.
  • Bayer Healthcare
  • Biogen Inc.
  • Blueprint Medicines Corp
  • Eli Lilly and Company
  • Merck & co Inc.
  • Novartis
  • Pfizer Inc.

Methodology

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...